Episode 299: Androgen Receptor Ligand-Directed Degrader BMS-986365

Dana Rathkopf describes the phase 1 data for the androgen receptor ligand-directed degrader in prostate cancer, and discusses more about this new class of drugs.
Dr. Rathkopf is an attending physician at Memorial Sloan Kettering Cancer Center specializing in advanced prostate cancer.